BioCryst Pharmaceuticals (BCRX) Gains FDA Approval for ORLADEYO Pediatric Formulation
BioCryst Pharmaceuticals (BCRX) announced FDA approval of ORLADEYO oral pellets for pediatric HAE patients aged 2 to <12 years.
$BCRX
BioCryst Pharmaceuticals (BCRX) Receives FDA Approval for ORLADEYO Oral Pellets in Pediatric HAE Patients
BioCryst Pharmaceuticals (BCRX) announced FDA approval of ORLADEYO oral pellets for pediatric hereditary angioedema patients aged 2 to <12 years.
BioCryst Pharmaceuticals (BCRX) Receives FDA Approval for ORLADEYO Oral Pellets in Pediatric HAE Patients Aged 2-12
BioCryst Pharmaceuticals (BCRX) announced FDA approval of ORLADEYO oral pellets for pediatric HAE patients aged 2 to <12 years, expanding its market reach.
BioCryst Pharmaceuticals (BCRX) Announces Board Leadership Transition: Hutson Retires, Milano Elected Chair
BioCryst Pharmaceuticals (BCRX) announced the retirement of Nancy J. Hutson, Ph.D., from its Board of Directors and the election of Vincent J. Milano as the next Chair.